RT Journal Article
SR Electronic
T1 A Large-Scale Proteomics Resource of Circulating Extracellular Vesicles for Biomarker Discovery in Pancreatic Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.13.23287216
DO 10.1101/2023.03.13.23287216
A1 Bockorny, Bruno
A1 Muthuswamy, Lakshmi
A1 Huang, Ling
A1 Hadisurya, Marco
A1 Lim, Christine Maria
A1 Tsai, Leo L.
A1 Gill, Ritu R.
A1 Wei, Jesse L.
A1 Bullock, Andrea J.
A1 Grossman, Joseph E.
A1 Besaw, Robert J.
A1 Narasimhan, Supraja
A1 Tao, W. Andy
A1 Perea, Sofia
A1 Sawhney, Mandeep S.
A1 Freedman, Steven D.
A1 Hidalgo, Manuel
A1 Iliuk, Anton
A1 Muthuswamy, Senthil K.
YR 2024
UL http://medrxiv.org/content/early/2024/07/19/2023.03.13.23287216.abstract
AB Pancreatic cancer has the worst prognosis of all common tumors. Earlier cancer diagnosis could increase survival rates and better assessment of metastatic disease could improve patient care. As such, there is an urgent need to develop biomarkers to diagnose this deadly malignancy. Analyzing circulating extracellular vesicles (cEVs) using ‘liquid biopsies’ offers an attractive approach to diagnose and monitor disease status. However, it is important to differentiate EV-associated proteins enriched in patients with pancreatic ductal adenocarcinoma (PDAC) from those with benign pancreatic diseases such as chronic pancreatitis and intraductal papillary mucinous neoplasm (IPMN). To meet this need, we combined the novel EVtrap method for highly efficient isolation of EVs from plasma and conducted proteomics analysis of samples from 124 individuals, including patients with PDAC, benign pancreatic diseases and controls. On average, 912 EV proteins were identified per 100µL of plasma. EVs containing high levels of PDCD6IP, SERPINA12 and RUVBL2 were associated with PDAC compared to the benign diseases in both discovery and validation cohorts. EVs with PSMB4, RUVBL2 and ANKAR were associated with metastasis, and those with CRP, RALB and CD55 correlated with poor clinical prognosis. Finally, we validated a 7-EV protein PDAC signature against a background of benign pancreatic diseases that yielded an 89% prediction accuracy for the diagnosis of PDAC. To our knowledge, our study represents the largest proteomics profiling of circulating EVs ever conducted in pancreatic cancer and provides a valuable open-source atlas to the scientific community with a comprehensive catalogue of novel cEVs that may assist in the development of biomarkers and improve the outcomes of patients with PDAC.Competing Interest StatementB.B. reports Research Funding: Agenus Inc, NanoView Bioscience; Travel Expenses: Erytech Pharma; Advisory Board and Consulting: Blueprint Medicines, Bioline Rx. A.B. reports Advisory/Consulting with Exelixis and Geistlich Pharma. A.I. and W.A.T. are principals at Tymora Analytical Operations, which developed EVtrap beads. M.H. reports grants from Weill Cornell Medicine; personal fees from Agenus, BMS, Oncomatrix, Khar, Inxmed, Genchem, Cantargia, and Fibrogen outside the submitted work; patent for Method for ACT in PDAC licensed to Peaches SL; and Director of BMS. S.K.M. owns stocks and is a member of the Scientific Advisory Board of KAHR Medical. The remaining authors declare no related competing interests.Funding StatementB.B. was supported in part through UM1 (CA186709-06). S.D.F. was supported in part through the Barbara Janson and Arthur Hilsinger Pancreatology Fellowship. Institutional startup funds and UO1 (CA224193) to S.K.M., and seed grant from Hirschberg Foundation for Pancreatic Cancer Research to L.H. We thank members of the Muthuswamy laboratory for their critical input throughout the development of this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Dana Farber Harvard Cancer Center Institutional Review Board.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data presented all be made available upon request